Abstract
Background: Non–steroidal anti–inflammatory drugs (NSAIDs) and weak opioids such as tramadol are cornerstones of multimodal analgesia, particularly in settings with limited access to potent opioids. However, cross–class equianalgesic data comparing these agents remain scarce. This pilot randomised controlled trial aimed to explore the analgesic equivalence of ketorolac, diclofenac, and tramadol administered as premedication in patients undergoing minimally invasive surgery. Methods: In this double–blind, parallel–group pilot trial, 30 patients scheduled for elective minimally invasive surgery (28 laparoscopic cholecystectomies, 2 laparoscopic abdominal wall repairs) under balanced general anaesthesia were randomised to receive intravenous tramadol 150 mg, ketorolac 60 mg, or diclofenac 150 mg 45 minutes before skin incision. The primary outcome was pain intensity measured using the Numerical Rating Scale (NRS, 0–10) at recovery room arrival (T0) and at 30 (T1), 60 (T2), and 90 (T3) minutes thereafter. Secondary outcomes included Verbal Rating Scale (VRS) scores, rescue morphine consumption, and safety. Between–group comparisons were performed using Kruskal–Wallis tests with Dunn post–hoc corrections; within–group trajectories were analysed using Friedman tests. Effect sizes were estimated with epsilon–squared and Kendall's W. Results: All 30 patients completed the study. At T0 and T1, NRS scores were higher in the ketorolac group (median 1.5 and 3, respectively) compared with tramadol and diclofenac (both median 0 at T0; T1: tramadol 1, diclofenac 2; p < 0.05 for both). However, by T2 and T3, all three groups converged to a median NRS of 2 (p > 0.05 for between–group differences). Rescue analgesia requirements at T1 were 0/10 (tramadol), 3/10 (ketorolac), and 2/10 (diclofenac), with no statistically significant differences (p = 0.19). No hypersensitivity reactions occurred. Within–group analyses showed consistent pain trajectories, with Kendall's W ranging from 0.31 (ketorolac) to 0.64 (tramadol). Conclusions: In this pilot study, equianalgesic doses of tramadol, ketorolac, and diclofenac provided comparable postoperative pain control over 90 minutes following minimally invasive surgery. All agents were well tolerated. These findings support the feasibility of a larger definitive trial and offer clinically useful guidance for analgesic selection in resource-limited settings. Keywords: Analgesic equivalence, NSAIDs, tramadol, ketorolac, diclofenac, postoperative pain, minimally invasive surgery, pilot randomised controlled trial
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT07500454
Funding Statement
Funding and equipment were provided by the Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado Hospital Regional "General Ignacio Zaragoza".
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of the Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado Hospital "Gral. Ignacio Zaragoza", gave ethical approval for this work, with registration number: ISSSTE RPI #403-2024.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
In this updated version, the Graphical Abstract was fixed. Now it is the correct one.
Data Availability
All data produced in the present study are available upon reasonable request to the authors. Deidentified individual participant data will be made available following article publication, on GitHub <https://github.com/phabel-LD>, along with all analysis code.
